Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cannabidiol (seizures in tuberous sclerosis complex) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Systematic review about effectiveness of digital pathology as a diagnostic tool for pathology and cytopathology]
2021	Health Information and Quality Authority (HIQA)	Advice to the National Public Health Emergency Team: Derogation of healthcare workers, who are deemed close contacts, from restricted movements following COVID-19 vaccination
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Coping strategies in complex medical situations - the example of coronary heart disease]
2021	NIHR Health Services and Delivery Research programme	Models of generalist and specialist care in smaller acute hospitals: an exploratory study
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: noninvasive fetal RhD genotyping using maternal plasma]
2021	Scottish Health Technologies Group (SHTG)	Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V]
2021	Health Information and Quality Authority (HIQA)	Public health measures and strategies to limit the spread of COVID-19: an international review [Update]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[The potential influence of socio-demographical factors on access to and results of rehabilitation]
2021	The Federal Joint Committee (G-BA)	[Pharamceutical Directive/Annex XII: Avapritinib (gastrointestinal stromal tumours)]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tucatinib (breast cancer) - Addendum to Commission A21-26]
2021	Health Information and Quality Authority (HIQA)	Public health measures and strategies to limit the spread of COVID-19: an international review: Antigen testing in asymptomatic individuals in community settings
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice venetoclax (Venclyxto®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021	Health Information and Quality Authority (HIQA)	Current public health guidance for community settings and infection prevention and control measures in healthcare settings for COVID-19: a rapid review
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Speech therapy for aphasia]
2021	Swiss Federal Office of Public Health (FOPH)	Statins in the primary prevention of cardiovascular events and mortality in Switzerland
2021	NIHR Health Technology Assessment programme	Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: microbiological stool testing in adults and children with diarrhea: relevance and measures to promote judicious use]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35]
2021	Swiss Federal Office of Public Health (FOPH)	Vertebroplasty or kyphoplasty in painful osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: pertussis - diagnostic modalities and trajectory]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36]
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Efficacy and safety of yoga on selected clinical conditions]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma, adjuvant) - Addendum to Commission A21-39]
2021	Swiss Federal Office of Public Health (FOPH)	Chondroitin sulfate in osteoarthritis
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Addendum to commission H20-01]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book]
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatment for postpartum psychiatric disorders - an evidence map]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice drospirenon-estetrol (Drovelis®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021	Adelaide Health Technology Assessment (AHTA)	Small gene panel testing for non-small cell lung carcinoma
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2021	Adelaide Health Technology Assessment (AHTA)	Whole genome sequencing of antimicrobial-resistant pathogens
2021	Malaysian Health Technology Assessment (MaHTAS)	Platelet rich plasma, platele-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021	Adelaide Health Technology Assessment (AHTA)	Genetic testing for childhood hearing impairment
2021	NIHR Health Technology Assessment programme	Paclitaxel-assisted balloon angioplasty of venous stenosis in haemodialysis access: PAVE RCT
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Clinical effects of preoperative i.v. iron infusion in patients with colorectal cancer and iron-deficiency anemia
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Perioperative antibiotics for prevention of infections in arterial reconstructions with vascular prostheses]
2021	NIHR Health Technology Assessment programme	DRAFFT 2: Distal Radius Acute Fracture Fixation Trial 2
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice on the reassessment of tafamidis (Vyndaqel®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Clopidogrel versus ticagrelor as part of dual antiplatelet therapy for patients with acute coronary syndrome
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Venous irritation resulting from IV fosaprepitant
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy and safety of endovascular versus surgical arteriovenous fistula creation for hemodialysis
2021	NIHR Health Technology Assessment programme	Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: artificial intelligence-assisted diabetic retinopathy tele-screening]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Oral hygiene interventions to prevent ventilator-associated pneumonia (VAP)
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021	The Regional Health Technology Assessment Centre (HTA-centrum)	Effectiveness and safety of breast reduction surgery, compared with no surgery, in women with symptomatic breast hypertrophy
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice on subcutaneous buprenorphine (Buvidal®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021	Malaysian Health Technology Assessment (MaHTAS)	Driving simulator in healthcare
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021	NIHR Health Technology Assessment programme	Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	NIHR Health Technology Assessment programme	The Prognosis in Palliative care Study II (PiPS2)
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	Feasibility of a RCT of techniques for managing an impacted fetal head during emergency caesarean section: the MIDAS scoping study
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Berotralstat (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Key items for developing and implementing a high complexity/cost surgical implants registry for its postmarketing surveillance]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[National expert standards in nursing care]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Brentuximab Vedotin (reassessment after the deadline: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin, and Prednisone)]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Nutritional therapy in heart failure patients with malnutrition]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice for cladribine (Mavenclad®) – extension of further conditions
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of calcifediol (Hidroferol®)
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A20-61]
2021	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Automated storage and dispensing medication systems in hospital pharmacy services. Safety, effectiveness and efficiency]
2021	NIHR Health Technology Assessment programme	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation